| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
58,874 |
51,761 |
$1.97M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
10,446 |
9,027 |
$465K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,139 |
1,094 |
$151K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
8,952 |
4,155 |
$141K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,451 |
1,223 |
$81K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
745 |
688 |
$60K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
654 |
602 |
$45K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
401 |
375 |
$43K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,339 |
2,175 |
$38K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
4,549 |
3,918 |
$38K |
| 87430 |
|
2,333 |
2,163 |
$35K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
563 |
513 |
$32K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
357 |
342 |
$26K |
| 99490 |
Ccm add 20min |
2,894 |
2,586 |
$22K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
529 |
511 |
$21K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
5,876 |
3,490 |
$19K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
1,245 |
1,143 |
$12K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
346 |
317 |
$10K |
| 0012A |
|
258 |
251 |
$9K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
988 |
854 |
$9K |
| 0011A |
|
287 |
277 |
$8K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
1,417 |
569 |
$7K |
| Q2038 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) |
840 |
731 |
$6K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
257 |
225 |
$6K |
| 80050 |
General health panel |
140 |
128 |
$6K |
| 73630 |
|
616 |
262 |
$5K |
| 36415 |
Collection of venous blood by venipuncture |
1,810 |
1,403 |
$4K |
| 90651 |
|
252 |
215 |
$4K |
| 90734 |
|
209 |
169 |
$3K |
| 0001A |
|
74 |
74 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,521 |
1,150 |
$3K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
78 |
55 |
$3K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
78 |
55 |
$3K |
| 90688 |
|
315 |
278 |
$2K |
| 90670 |
|
640 |
560 |
$2K |
| 80061 |
Lipid panel |
128 |
116 |
$2K |
| G0451 |
Development testing, with interpretation and report, per standardized instrument form |
32 |
28 |
$2K |
| 84703 |
|
167 |
153 |
$2K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
50 |
38 |
$1K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
39 |
30 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
35 |
29 |
$1K |
| 59025 |
Fetal non-stress test |
41 |
25 |
$1K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
55 |
37 |
$1K |
| 0013A |
|
30 |
27 |
$964.80 |
| 0002A |
|
25 |
25 |
$920.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
83 |
51 |
$882.53 |
| 99000 |
|
562 |
445 |
$878.89 |
| 90715 |
|
136 |
128 |
$857.38 |
| 96161 |
|
129 |
100 |
$710.90 |
| 11721 |
|
57 |
51 |
$670.84 |
| 90698 |
|
561 |
484 |
$615.54 |
| 99307 |
|
244 |
200 |
$583.74 |
| 0134A |
|
22 |
15 |
$520.00 |
| 82248 |
|
66 |
62 |
$402.69 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
22 |
13 |
$390.00 |
| 90461 |
|
584 |
261 |
$378.36 |
| 90633 |
|
154 |
119 |
$349.71 |
| 90619 |
|
44 |
39 |
$301.16 |
| 90677 |
|
24 |
24 |
$257.09 |
| G0312 |
Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 5 to 15 mins time (this code is used for medicaid billing purposes) |
16 |
16 |
$233.76 |
| 83655 |
|
18 |
14 |
$223.74 |
| 85018 |
|
72 |
56 |
$164.09 |
| 85014 |
|
73 |
56 |
$161.06 |
| 11720 |
|
35 |
25 |
$119.50 |
| 11719 |
|
39 |
25 |
$114.91 |
| 3079F |
|
200 |
184 |
$100.00 |
| Q2036 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) |
167 |
137 |
$85.71 |
| 3074F |
|
1,274 |
1,204 |
$80.00 |
| 3078F |
|
1,074 |
1,025 |
$80.00 |
| 90648 |
|
16 |
14 |
$22.52 |
| 81003 |
|
26 |
18 |
$15.72 |
| 99406 |
|
13 |
13 |
$14.68 |
| 90680 |
|
229 |
202 |
$0.00 |
| 90744 |
|
145 |
129 |
$0.00 |
| 1125F |
|
59 |
50 |
$0.00 |
| 90696 |
|
15 |
15 |
$0.00 |
| 99072 |
|
244 |
238 |
$0.00 |
| 90687 |
|
75 |
67 |
$0.00 |